News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
finance.yahoo.com Earnings
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Vistra has delivered a very large 5 year return, yet on current checks the stock now looks closer to fairly valued than clearly cheap, which puts more focus on whether recent news and changing expectations justify the price you …
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Billionaire Peter Thiel has acquired a 1% stake in Argentina's Vista, a major oil company operating in the Vaca Muerta shale formation. This investment was disclosed in a U.S. Securities and Exchange Commission filing. Vista is one of the largest oil companies in the …
Summit Global Investments recently acquired a new position in Avista Corporation (NYSE:AVA) during the second quarter, purchasing 32,535 shares valued at approximately $1.33 million. This utility company is largely institutionally owned, with 85.24% of its stock held by institutional investors. Despite a cautious "Hold" …
Assenagon Asset Management S.A. has initiated a new $1.63 million investment in Avista Corporation (NYSE:AVA) by purchasing 39,860 shares in the second quarter. This move comes as other institutional investors, such as Goldman Sachs and Northwestern Mutual Wealth Management Co., also significantly increased their …
Vistagen Therapeutics (VTGN) announced a non-dilutive financing of up to $100 million with HealthCare Royalty Partners. This agreement extends the company's financial runway into 2027, allowing it to advance its late-stage clinical programs. The initial $50 million will support the Phase 3 PALISADE-2 trial …
Civista Bancshares (NASDAQ:CIVB) recently saw its stock price cross above its 200-day moving average, closing at $28.51 against an average of $25.43. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $30.25, and it exceeded quarterly EPS …
Vistagen Therapeutics reported a net loss of $13.0 million for Q1 2027, an improvement from the prior year, with revenue increasing to $1.5 million. Despite this, the company flagged substantial doubt about its ability to continue as a going concern due to high operating …
William Blair has reiterated its Hold rating for VistaGen Therapeutics (VTGN.US). The report from the investment firm indicates their continued neutral stance on the company's stock.
Power Companies are Seen as Infrastructure Assets Over the past decade, power producers were valued as cyclical businesses, as their performance was associated with commodity prices and weather patterns. This notion no longer holds, as the expansion of AI, industrial electrification, and data centers …
Sharemaestro market context Price below Trend Line 52 weeks -29.3% · Next-week setup negative 44.2%Chen Yu, through TCG Crossover funds, has reported a 6.7% warrant-based stake in Vistagen Therapeutics (VTGN) via an amended Schedule 13G/A filing. TCG Crossover I holds 1.8% and TCG Crossover II holds 5.1%, with Chen Yu being the sole managing member of both general …
Vistagen (VTGN) reported a narrower net loss of $13.0 million for Q1 FY2027, an improvement from $15.1 million in the prior-year quarter, largely due to increased revenue and reduced R&D and G&A expenses. While its lead drug fasedienol missed its primary endpoint in the …
Vistagen Therapeutics reported a narrower loss for Q1 fiscal 2027, with a basic and diluted loss of $0.30 per share and a net loss of $13.0M. The company saw a significant revenue increase to $1.5M, up 504.9% year-over-year, as it continues to develop therapies …
(RTTNews) - Vistagen Therapeutics Inc. (VTGN), a late clinical-stage biopharmaceutical company developing intranasal pherine therapies for neuropsychiatric and other disorders, reported first quarter fiscal 2027 results and provided a corporate update. Vistagen is developing rapid-onset intranasal pherine product candidates designed to target nose-to-brain neurocircuitry. …
Envista Holdings Corporation NVST raised its 2026 outlook after a stronger first half, putting greater emphasis on whether recent sales and profit gains can carry through the rest of the year. Higher revenue expectations and expanding margins support the earnings recovery. China pricing changes, …
Royal Bank of Canada significantly increased its stake in Visteon Corporation (NASDAQ:VC) by 103.2% in the first quarter, now owning 45,410 shares valued at $4.14 million. This move comes as institutional investors collectively hold 99.71% of Visteon's stock. Despite missing quarterly EPS estimates, the …
Vistagen announced its Q1 FY2027 results, reporting $1.476 million in revenue and a net loss of $13.03 million. The company ended the quarter with $31.7 million in cash, expecting these funds to support operations into 2027. Vistagen also highlighted upcoming FDA discussions regarding a …
This article announces that VistaGen Therapeutics Inc. has filed a Form 8K on August 14th. The brief news item from Investing.com provides no further details about the content of the filing but notes the stock symbol VTGN.
Vistagen announced its fiscal year 2027 first-quarter financial results, highlighting progress in its fasedienol program for social anxiety disorder, including plans for FDA engagement regarding a Phase 3 pathway. The company reported a net loss of $13.0 million, reduced R&D and G&A expenses due …
* VistaGen Therapeutics press release [https://seekingalpha.com/pr/20619736-vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update] (VTGN [https://seekingalpha.com/symbol/VTGN]): Q1 GAAP EPS of -$0.30 beats by $0.06. * Revenue of $1.48M (+516.7% Y/Y) beats by $1.31M. * Cash, cash equivalents, and marketable securities were $31.7 million as of June 30, 2026. Based on current operating …
Vista Energy, S.A.B. de C.V. (VIST) announced the repurchase of 50,000 Series A shares on August 13, 2026, for approximately MXN 56.7 million, excluding fees and VAT. The shares were bought back at a price of MXN 1,133.76 per share under an authorization from …
5 Insightful Analyst Questions From Envista's Q2 Earnings Call Envista's second quarter results were shaped by balanced growth across all major geographies and a continued focus on operational execution. Management pointed to resilient demand for dental care, especially in consumables and diagnostics, as a …
Envista Holdings Corp.'s Chief Administrative Officer, Thomas Coree K., has filed a Form 3 detailing his initial beneficial ownership of the company's equity. This includes various employee stock options, restricted stock units (RSUs) with vesting schedules, and notional phantom shares linked to Envista stock …
This article analyzes Vistra Corp. (VST) using AI models to provide trading strategies. It highlights a near-term strong sentiment potentially challenging persistent mid and long-term weakness, with support currently being tested. The analysis includes position, momentum breakout, and risk hedging strategies, along with multi-timeframe …
Envista Holdings Corporation NVST is showing a sharper earnings recovery after a solid second quarter, with stronger profitability and raised 2026 guidance strengthening the near-term case. The offset is valuation. NVST now trades above its five-year median forward earnings multiple, leaving less room for …
This article compiles recent news and updates for Vistra Corp (VST), primarily focusing on its Q2 2026 earnings. Key highlights include beating EPS estimates, higher pricing and Lotus assets boosting EBITDA, but derivative losses impacting revenues. Analyst reactions, including Jim Cramer's positive sentiment, and …
Vista Energy, S.A.B. de C.V. (NYSE: VIST) announced the repurchase of 50,000 Series A shares on August 12, 2026, at a price of Mexican Pesos $1,134.72 per share, totaling approximately Mexican Pesos $56,736,000. These repurchases were authorized by a shareholders' meeting on April 28, …
Search by ticker symbol or company name and select a result to open its chart.